Michal Oleksiejczuk’s second UFC fight will have to wait.

Oleksiejczuk was issued a one-year suspension Tuesday by the Nevada Athletic Commission (NAC) stemming from his failed drug test in relation to his Octagon debut at UFC 219. Oleksiejczuk tested positive in an in-competition drug screening ahead of the Dec. 30 bout, which initially saw him defeat Khalil Rountree via unanimous decision. Oleksiejczuk popped for the anti-estrogen agent clomiphene, a commission official told MMA Fighting.

In addition to the one-year suspension, Oleksiejczuk was fined $3,600 — 30% of his $12,000 purse — and will be required to submit a clean drug test before seeking relicensure. The Polish light heavyweight’s win over Rountree has also been overturned into a no-contest.

Oleksiejczuk joins a growing list of UFC athletes to test positive for clomiphene, a list which includes the likes of Jon Jones, Brock Lesnar, Jesse Taylor, and Nick Roehrick.

USADA still has yet to rule on the 23-year-old’s case, so Oleksiejczuk could potentially face further sanctions from the UFC’s drug-testing partner.

Oleksiejczuk (12-2, 1 NC) was initially scheduled to make his Octagon debut against Ion Cutelaba at UFC 217, however that fight was scrapped after Cutelaba suffered his own USADA violation.

Oleksiejczuk’s one-year NAC suspension ends on Dec. 30.